



# ISARIC/WHO Clinical Characterisation Protocol UK (CCP-UK) CASE REPORT FORM GUIDANCE

**FRONT PAGE 1 of 3** 

#### V10.5 04/04/2022

#### **DESIGN OF THE CCP-UK CASE REPORT FORM (CRF)**

This CRF is divided into a "ADMISSION" form (4 pages), a "DAILY" form (1 pages) for daily clinical and laboratory and data, an "OUTCOME" form (4 pages) and a "WITHDRAWAL" form (1 page).

#### **HOW TO USE THIS CRF**

The CRF is designed to complement the **Tier** of activity that a site has capacity and capability to work to. This is likely to vary over the course of an outbreak. The decision on which **Tier** to use is up to the Local Principal Investigator and does not need discussion with the Chief Investigator. No delegation log is required by sponsor or protocol, but may be by local R&D policy. The REDCAP data upload is considered this primary record and will be archived by the study team.

#### IMPORTANT CHANGES effective from 4th April 2022

Tier Zero sites	<ul> <li>With consent, please enrol all cases of admissions (and those discharged) with confirmed or suspected exposure of Public Health Interest as defined by a public health agency or the CCP-UK study team</li> <li>Please complete the ADMISSION CRF and DAILY CRF for the first day of hospital admission (day 1), and then the DAILY CRF again for each following day, then the OUTCOME CRF at day 28, discharge, or death (whichever occurs first)</li> <li>Current activation criteria:         <ul> <li>Elevated liver transaminases in child &lt;16yrs, and not due to other diagnoses such as hepatitis viruses A-E, autoimmune hepatitis, or poisoning. Elevated transaminases defined as ALT &gt;400 iU/L and/or AST &gt;400 iU/L. These criteria may be refined as knowledge is gained.</li> </ul> </li> </ul>
Tier 1 & 2 sites	With consent, enrol all cases as per T0, AND where there is site capacity, sample for Tier 1 or Tier 2 according to the protocol schedule



### PARTICIPANT ID I \_\_ I I I


On each page above here write site code & participant number as per this example (participant number can be 4 or 5 digits depending on number of recruits)

#### **CASE REPORT FORMS**

#### **FRONT PAGE 2 of 3**

#### **GENERAL GUIDANCE**

- The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date or deceased after admission.
- Participant Identification Numbers consist of a 5-digit CPMS / ODS site code and a 4 or 5-digit participant number. You should obtain a site code by contacting your local R&D office or CCP@liverpool.ac.uk
- Participant numbers should be assigned sequentially for each site beginning with 0001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, it is acceptable to assign numbers in blocks. E.g. Ward X will assign numbers from 0001 onwards and Ward Y will assign numbers from 5001 onwards. Enter the Participant Identification Number at the top of every page.
- Please generate a new subject ID for each re-admission
- CRF data should be entered to the central database at https://ncov.medsci.ox.ac.uk
- REDCap registration access is obtained by contacting <a href="mailto:CCP.REDCap@liverpool.ac.uk">CCP.REDCap@liverpool.ac.uk</a>
- Please contact us at <a href="mailto:CCP.REDCap@liverpool.ac.uk">CCP.REDCap@liverpool.ac.uk</a> for help with database problems.



#### FRONT PAGE 3 of 3

- Ideally complete every line of every section, except for where the instructions say to skip a section based on certain responses. This may not be possible in surge conditions.
- ➤ Selections with square boxes (□) are single selection answers (choose one answer only). Selections with circles (o) are multiple selection answers (choose as many answers as are applicable).
- Some fields are considered URGENT AND ESSENTIAL. These are marked BOLD AND UNDERLINED IN ALL CIRCUMSTANCES PLEASE PRIORITISE THESE DATA POINTS FOR URGENT UPLOAD.
- Mark 'N/K' for any results of laboratory values that are not known or not available.
- Avoid recording data outside of the dedicated areas. Sections are available for recording additional
- We recommend writing clearly in black ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) when you choose the corresponding answer. To make corrections, strike through (-----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- In the case of a participant transferring between study sites, such as to a Nightingale Hospital, or other surge facility, it is preferred to maintain the same Participant Identification Number across the sites. When this is not possible a new Participant Identification Number should be assigned, the transferred participant will be linked by their identifiable data.
- Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder.
- These four FRONT PAGES do not need to be retained.
- NEVER SEND CRFs to anyone by unsecure email or post.
- See the training guide on how to send consent to CCP@liverpool.ac.uk using [SECURE] encryption
- The Dalhousie University Clinical Frailty Score is provided below for your reference.

#### Clinical Frailty Scale\*



I Very Fit – People who are robust, active, energetic and motivated. These people commonly exercise regularly. They are among the fittest for their age.



2 Well – People who have no active disease symptoms but are less fit than category I. Often, they exercise or are very active occasionally, e.g. seasonally.



3 Managing Well – People whose medical problems are well controlled, but are not regularly active beyond routine walking.



4 Vulnerable – While not dependent on others for daily help, often symptoms limit activities. A common complaint is being "slowed up", and/or being tired during the day.



 $\begin{tabular}{ll} 5 & \textbf{Mildly Frail} - \textbf{These people often have more} \\ \end{tabular}$ evident slowing, and need help in high order IADLs (finances, transportation, heavy housework, medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation and housework



6 Moderately Frail – People need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cuing, standby) with dressing.



7 Severely Frail – Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within ~ 6 months).



8 Very Severely Frail - Completely dependent. approaching the end of life. Typically, they could not recover even from a minor illness.



9. Terminally III - Approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise evidently frail.

#### Scoring frailty in people with dementia

The degree of frailty corresponds to the degree of dementia. Common symptoms in mild dementia include forgetting the details of a recent event, though still remembering the event itself, repeating the same question/story and social withdrawal.

In moderate dementia, recent memory is very impaired, even though they seemingly can remember their past life events well. They can do personal care with prompting.

In severe dementia, they cannot do personal care without help

- \* I. Canadian Study on Health & Aging, Revised 2008. 2. K. Rockwood et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489-495.

© 2007-2009. Version I.2. All rights reserved. Geriatric Medicine Research, Dalhousie University, Halifax, Canada. Permission granted to copy for research and educational purposes only.





DADTICIDANT ID I		1 1	1 1	1 1		1 1			1.1
PARTICIPANT ID I	11	1 1	11	1 1		1 1	11	11	11

### ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK ADMISSION FORM page 1 of 4

Date of enrolment [ D ][ D ]/[ M ][ M ]/[2 ][ O ][ Y ][ Y ] Site Location **CLINICAL INCLUSION CRITERIA Proven infection with pathogen of Public Health Interest**: ☐ YES ☐ NO OR High suspicion of exposure to pathogen, noxious agent or harmful energy of Public Health Interest: ☐ YES ☐ NO N.B. This does **not** relate to covid-19 exposure. This does include children with hepatitis of unknown cause. **DEMOGRAPHICS** Sex at Birth: ☐ Male ☐ Female ☐ Not specified Date of birth [ □ ][ □ ]/[ ⋈ ]/[ ⋈ ]/[ ∀ ][ ∀ ][ ∀ ][ ∀ ] If date of birth is Not Known (N/K) record Age: [\_\_][\_\_]years OR [\_\_][\_\_]months Postcode: [\_\_][\_\_][\_\_] [\_\_] England & Wales NHS number, Scotland CHI: [\_\_][\_\_][\_\_] [\_\_][\_\_] [\_\_][\_\_][\_\_] NB Northern Ireland Health & Care Number is not being collected at this time Ethnic group (check all that apply): OArab OBlack OEast Asian OSouth Asian OWest Asian OLatin American OWhite OAboriginal/First Nations OOther: □N/K Employed as a Healthcare Worker? ☐YES ☐NO ☐N/K Pregnant? ☐ YES ☐ NO ☐ N/K If YES: Gestational weeks assessment: [\_\_\_][\_\_\_] weeks POST PARTUM (within six weeks of delivery)? ☐YES ☐NO or ☐N/K (skip this section - go to INFANT) Pregnancy Outcome: □Live birth □Still birth Delivery date: [\_D\_](\_D\_]/(\_M\_](\_M\_]/(\_2\_](\_0\_](\_Y\_](\_Y\_) Has infant(s) been tested for Mother's infection? □YES □NO □N/K If YES: □Positive □Negative IF POSITIVE PLEASE COMPLETE A SEPARATE CASE REPORT FORM FOR THE INFANT(s) INFANT – Less than 1 year old?  $\square$ YES  $\square$ NO (skip this section) Birth weight: [\_\_\_].[\_\_\_]kg □N/K Gestational: ☐ Term birth (≥37wk GA) ☐ Preterm birth (<37wk GA) if <37wk Estimated gestation weeks ☐ N/K

Breastfed? ☐YES ☐NO ☐N/K If YES: ☐Currently breastfed ☐Breastfeeding discontinued ☐N/K



Oxygen saturation: [\_ ][\_ ][\_ ]%

PARTICIPANT ID I \_\_\_ I I\_\_\_ I

ADMISSION FORM page 2 of 4

ONSET AND ADMISSION						
Date of first/earliest symptom: [_D_](_D_]/[_M_](_M_]/[_2_](_0_](_Y_](_Y_] OR						
Admission date at this facility: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]						
Transfer from other facility? $\Box$ YES-other facility is a study site $\Box$ YES-other facility is not a study site $\Box$ NO $\Box$ N/K						
If YES: Name of prior facility: \Bigcup N/K						
If YES: Admission date at previous facility (DD/MM/YYYY): [ D ][ D ]/[ M ][ M ]/[ 2 ][ 0 ][ Y ][ Y ]						
If YES-Study Site: Participant ID # at previous facility: I II						
OR □Same as above						
ON LIBATILE as above						
VITAL SIGNS AT HOSPITAL ADMISSION -first available data at presentation/Admission to the facility.  (This section should refer to data from the date of admission to this facility)						
Temperature: [     -   °C HR: [        beats per minute RR: [     breaths per minute						
Systolic BP: [_] [_]mmHg Diastolic BP: [_] [_]mmHg Severe dehydration: □YES □NO □N/K						
Sternal capillary refill time >2seconds						

On: □Room air □Any Oxygen therapy □N/K

SIGNS AND SYMPTOMS- This section should refer to the start of this episode None (asymptomatic) □								
History of fever	□YES □NO □N/K	Lower chest wall indrawing	□YES □NO □N/K					
<u>Cough</u>	□YES □NO □N/K	<u>Headache</u>	□YES □NO □N/K					
with sputum production	□YES □NO □N/K	<u>Altered</u>	□YES □NO □N/K					
bloody sputum/haemoptysis	□YES □NO □N/K	consciousness/confusion	□YES □NO □N/K					
Sore throat	□YES □NO □N/K	<u>Seizures</u>	□YES □NO □N/K					
Runny nose (Rhinorrhoea)	□YES □NO □N/K	Abdominal pain	□YES □NO □N/K					
Ear pain	□YES □NO □N/K	Vomiting / Nausea	□YES □NO □N/K					
	□YES □NO □N/K	<u>Diarrhoea</u>	□YES □NO □N/K					
Wheezing	•	<u>Conjunctivitis</u>	□YES □NO □N/K					
<u>Chest pain</u>	□YES □NO □N/K	Skin rash	□YES □NO □N/K					
Muscle aches (Myalgia)	□YES □NO □N/K	Skin ulcers	□YES □NO □N/K					
Joint pain (Arthralgia)	□YES □NO □N/K	<u>Lymphadenopathy</u>	□YES □NO □N/K					
<u>Fatigue / Malaise</u>	□YES □NO □N/K	Bleeding (Haemorrhage)	□YES □NO □N/K					
Shortness of breath (Dyspnoea)	□YES □NO □N/K	If Bleeding: specify site(s):						
Disturbance or loss of taste	□YES □NO □N/K	Disturbance or loss of smell	□YES □NO □N/K					
(Ageusia ) Jaundice	□YES □NO □N/K	(Anosmia)						
***************************************								

PARTICIPANT ID I_		<u> </u>		-	-	II	ll	lI
								Page 3 of 4

CO-MORBIDITIES (existing)	No	comork	idities 🗆			
Chronic cardiac disease, including congenital heart disease. (not hypertension)	□YES □NO	□n/k	Obesity (as defined by clinical staff)	□YES	□NO	□N/K
Hypertension (physician diagnosed)	□YES □NO	□N/K	Diabetes and Type	□YES	□NO  2 □	N/K
Chronic pulmonary disease (not asthma)	□YES □NO	□n/ĸ	Diabetes (any) with complications	□YES	□по	□n/ĸ
Asthma (physician diagnosed)	□YES □NO	□n/k	Diabetes (any) without complications	□YES	□no	□n/k
Chronic kidney disease	□YES □NO	□n/k	Rheumatologic disorder	□YES	□NO	□n/k
Moderate / severe liver disease	□YES □NO	□n/k	<u>Dementia</u>	□YES	□NO	□n/k
Mild liver disease	□YES □NO	□n/k	<u>Malnutrition</u>	□YES	□NO	□n/k
Chronic neurological disorder	□YES □NO	□n/k	Smoking □YES □Never smoked □F	ormer sn	noker	□n/k
Malignant neoplasm	□YES □NO	□n/k	Other relevant risk factor			
Chronic hematologic disease	□YES □NO	□N/K	□YES □NO □N/K			
AIDS / HIV	□YES □NO	□N/K	If yes, specify			

Is the patient thought to be a member of a CLINICALLY EXTREMELY VULNERABLE GROUP No□ NK□						
Solid organ transplant recipients: $\square$ YES $\square$ NO $\square$ N/K						
People with specific cancers: $\square$ YES $\square$ NO $\square$ N/K						
<ul> <li>people with cancer who are undergoing active chemotherapy</li> </ul>						
<ul> <li>people with lung cancer who are undergoing radical radiotherapy</li> </ul>						
<ul> <li>people with cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at any stage of treatment</li> </ul>						
<ul> <li>people having immunotherapy or other continuing antibody treatments for cancer</li> </ul>						
<ul> <li>people having other targeted cancer treatments which can affect the immune system, such as protein kinase inhibitors</li> </ul>						
<ul> <li>people who have had bone marrow or stem cell transplants in the last 6 months, or who are still taking immunosuppression drugs</li> </ul>						
People with <u>severe</u> respiratory conditions including all cystic fibrosis, severe asthma requiring daily oral steroid or injectable maintenance therapy and severe chronic obstructive pulmonary requiring oxygen (COPD): $\Box$ YES $\Box$ NO $\Box$ N/K						
People with rare diseases and inborn errors of metabolism that significantly increase the risk of infections (such as Severe combined immunodeficiency (SCID), homozygous sickle cell): $\Box$ YES $\Box$ NO $\Box$ N/K						
People on immunosuppression therapies sufficient to significantly increase risk of infection: ☐YES ☐NO ☐N/K						
Women who are pregnant with significant heart disease, congenital or acquired: ☐YES ☐NO ☐N/K						



PARTICIPANT ID I	1 1	1 11	11 11	11 1	1 11 1	1 1

Page 4 of 4

 CLINICAL FRAILTY SCORE for people age over 18 years

 With reference to the Dalhousie University Clinical Frailty Score (see guidance page 3 of complete CRF)

 Clinical Frailty Score
 [\_\_\_] value 1 to 9 or □N/K

 CURRENT MEDICATION ON ADMISSION

 Record medication the patient is currently taking or has taken within the past 14 days

 Medication name (generic name preferred-please write in CAPITALS):



PARTICIPANT ID I	11	11	11	1.1		1.1	11	11	П	
------------------	----	----	----	-----	--	-----	----	----	---	--

## ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK DAILY FORM Page 1 of 1

DAILY TREATMENT (complete every line):	
DATE OF ASSESSMENT (DD/MM/YYYY): [_D_][_D_]/[_M_]  Record the worst value between 00:00 to 24:00 on day of assessment days of assessment (DD/MM/YYYY): [_D_][_D_]/[_M_]	
Is the patient in a high-level care area i.e. admitted to ICU/ITU/II	MC/HDU □YES □NO □N/K
Highest Temperature: [_ ][].[] °C □N/K	
Any Supplemental Oxygen ☐YES ☐NO ☐N/K FiO₂ (0.21-1.0) [	
Oxygen saturation DYES DNO DN/K SpO <sub>2</sub> [ ][ ][ ]%	(lowest) RR: [ ][ ]breaths per minute (highest) □N/K
AVPU Alert[ ] Verbal[ ] Pain [ ] Unresponsive[ ] or [	N/K Glasgow Coma Score (GCS / 15) [ ][ ] or □N/K
Is the patient currently receiving, or has received (from 00:00 to	
Non-invasive respiratory support (e.g. NIV, BIPAP, CPAP)? □YES  High-flow nasal canula? □YES □NO □N/K ECLS/ECMO?	
DAILY LABORATORY RESULTS	
Record the values of laboratory results taken between 00:00 to 24 blood draw taken closest to midday)	
Done □YES □NO □N/K <u>Haemoglobin</u> □g/L or □g/c	
Done □YES □NO □N/K <u>WBC count</u> □x10 <sup>9</sup> /L or	·
Done □YES □NO □N/K Lymphocyte count	
Done □YES □NO □N/K Neutrophil count	
Done □YES □NO □N/K Platelets □x10°/L or □	
	Done STES STOND STONE ST
	Done YES NO N/K AST/SGOT iU/L
Done □YES □NO □N/K Glucose □ □mmol/L or □m  Done □YES □NO □N/K Blood Urea Nitrogen (urea) □	
Done □YES □NO □N/K Lactate□mmol/L or □	
	e □YES □NO □N/K Procalcitonin [][].[]ng/mL
Done □YES □NO □N/K <u>CRP [ ][ ][ ].[ ]</u> mg/L	
Done □YES □NO □N/K eGFR mL/min/1.73 m² <b>O</b> CK	D-EPI <b>O</b> MDRD <b>O</b> CG
Most recent HbA1c	_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
Chest X-Ray /CT performed? ☐YES ☐NO ☐N/K IF Yes: We	re infiltrates present? □YES □NO □N/K
ISARIC CCP-UK RESEARCH SAMPLES	
Was a biological sample taken for research on this day?	□YES □NO
If yes, please record the KIT number:	KIT NUMBER [ C ] [ C ] [ P ] [ ] [ ] [ ] [ ]



PARTICIPANT ID I	1.1	11	1.1	1.1		11	11	11	П	- 1
------------------	-----	----	-----	-----	--	----	----	----	---	-----

### **ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK**

OUTCOME FORM Page 1 of 4

#### **DIAGNOSTIC TESTING**

<u>Was diagnostic testing done during this illness episode</u>? **TYES\* NO N/K** \*Should be YES as this is key eligibility criteria \*Please record the detail of any COVID-19 / SARS2-CoV-2 test which may have been done in the community

Section 1: Diagnosis Summary ( Virus PCR or antigen tests -NOT serology/antibody tests)								
COVID-19 / SARS-CoV-2	☐ Tested POSITIVE	☐ Tested NEGATIVE	□ NOT TESTED					
Influenza virus  NB: Please do not enter Haemophilus influenza or parainfluenza virus here	☐ Tested POSITIVE, please confirm type: ☐ A/H3N2 ☐ A/H1N1pdm09 ☐ A/H7N9	☐ Tested NEGATIVE	□ NOT TESTED					
- enter them under "other" below	☐ A not typed ☐ Other A ☐ B not typed ☐ Other typed ☐ Other type (specify):							
Respiratory syncytial virus	☐ Tested POSITIVE	☐ Tested NEGATIVE	□ NOT TESTED					
<u>Adenovirus</u>	☐ Tested POSITIVE	☐ Tested NEGATIVE	□ NOT TESTED					
<u>Hepatitis viruses</u>	☐ Tested POSITIVE, please confirm type: ☐ A ☐ B ☐ C ☐ D ☐ E ☐ Other type (specify):	☐ Tested NEGATIVE	□ NOT TESTED					
Poisoning	☐ Tested POSITIVE, please confirm type: ☐ Paracetamol ☐ Other type (specify):	☐ Tested NEGATIVE	□ NOT TESTED					
<u>Other</u>	☐ Tested POSITIVE Please specify :							

#### **Section 2: Pathogen Testing Details** (Please record the details of all tests carried out during this illness episode -including the details of the tests indicated above). **Collection Date** Pathogen **Biospecimen Type** Result (DD/MM/YYYY) Tested/Detected ONasal/NP swab OThroat swab OCombined nasal/NP + throat swab **O**Positive OSputum **O**BAL **O**ETA **O**Negative D D / M M /202 Y **O**Urine OStool/rectal swab OBlood **O**Unknown OOther, Specify: OThroat swab ONasal/NP swab OCombined nasal/NP + throat swab **O**Positive OSputum **O**BAL **O**ETA **O**Negative D D / M M /202 Y OStool/rectal swab OBlood **O**Urine **O**Unknown OOther, Specify: ONasal/NP swab OThroat swab OCombined nasal/NP + throat swab **O**Positive OSputum **O**BAL **O**ETA **O**Negative D\_ D\_ /\_M\_ M\_ /202 \_Y **O**Urine OStool/rectal swab OBlood **O**Unknown OOther, Specify: ONasal/NP swab OThroat swab OCombined nasal/NP + throat swab **O**Positive OSputum **O**BAL **O**ETA **O**Negative D\_D\_/\_M\_\_M\_/202\_Y **O**Urine OStool/rectal swab OBlood **O**Unknown Other, Specify:



**OUTCOME FORM** 

PARTICIPANT ID I	_		-		_l
					Page 2 of 4

MEDICATION: While hospitalised or at o	discharge, were any	of the following administere	d?				
Antiviral agent? □YES □NO □N/K If YES,	tick all the apply:						
ORibavirin OOseltamivir (Tamiflu®)	<b>O</b> Zanamivir <b>O</b> Rem	ndesivir <b>O</b> Other or novel antivi	iral				
Antibiotic? □YES □NO □N/K If YES: s	pecify type(s):						
Corticosteroid? □YES □NO □N/K							
Antifungal agent? ☐YES ☐NO ☐N/K If YES: which							
Off-label / Compassionate Use medications?   Off-label / Compassionate Use medications   Off-label / Compassionate Use medications							
TREATMENT: At ANY time during hospit	alisation, did the pa	tient receive/undergo:					
ICU or High Dependency Unit admission? □	res □no □n/k	If YES, total duration:	days <b>O</b> still in ICU/HDU				
If NO, □Not indicated □Not appropriate*							
(*Advanced care plan/discussion documente		_	l ward)				
Date of ICU/HDU admission: [_D	_][_D_]/[_M_][_M_]/	202[_Y_] □N/K					
ICU/HDU discharge date: [_D_][_D_]/[_M_][_M_]/202[_Y_]							
Any Oxygen therapy? □YES □NO □N/K	High-flow nasal	canula? □YES □NO □N/K					
Non-invasive ventilation? (e.g. BIPAP, CPAP)	□YES □NO □N/K						
Invasive ventilation (Any intubation)?	□YES □NO □N/K	If YES, total duration:	days <b>O</b> still on				
Prone Ventilation?	□YES □NO □N/K						
Inhaled Nitric Oxide?	□YES □NO □N/K						
Tracheostomy inserted?	□YES □NO □N/K						
Extracorporeal (ECMO) support?	□YES □NO □N/K	If YES, total duration:	days <b>O</b> still on				
Renal replacement therapy (RRT) or dialysis?	□YES □NO □N/K	If YES, total duration:	days <b>O</b> still on				
Inotropes/vasopressors?	□YES □NO □N/K	If YES, total duration:	days <b>O</b> still on				
<u>Liver Transplant</u>	□YES □NO □N/K	If YES, date [_D_][_D_]/[_M_	][_M_]/ 202[_Y_] □N/K				
Kidney Transplant	□YES □NO □N/K	If YES, date [_D_][_D_]/[_M_	][_M_]/ 202[_Y_] □N/K				




**OUTCOME FORM** 

PARTICIPANT ID	1 1	1 1	1 1		l I	I I	l I	I II

Page 3 of 4

COMPLICATIONS: At any	time du	ring ho	spitalisation	did the patient experience:		No com	plications 🗆
Viral pneumonia	□YES	□ио	□n/k	Cardiac ischemia	□YES	□no	□n/k
Bacterial pneumonia	□YES	□no	□n/k	Cardiac arrest	□YES	□no	□n/k
Acute Respiratory Distress Syndrome	□YES	□no	□n/K	Bacteraemia	□YES	□no	□n/k
Cryptogenic organizing pneumonia (COP)	□YES	□no	□n/K	Coagulation disorder / Disseminated Intravascular Coagulation	□YES	□no	□n/k
Pneumothorax	□YES	□ио	□n/k	Deep vein thrombosis	□YES	□ио	□n/k
Pleural effusion	□YES	□ио	□n/k	Pulmonary thromboembolism	□YES	□no	□n/k
Bronchiolitis	□YES	□ио	□n/k	Anaemia	□YES	□ио	□n/k
Meningitis / Encephalitis	□YES	□ио	□n/k	Rhabdomyolysis / Myositis	□YES	□ио	□n/k
Seizure	□YES	□no	□n/K	Acute renal injury/acute renal failure	□YES	□no	□n/k
Stroke / Cerebrovascular accident	□YES	□NO	□n/K	Gastrointestinal haemorrhage	□YES	□no	□n/k
Other neurological complication	□YES	□no	□n/K	Pancreatitis	□YES	□no	□n/k
Congestive heart failure	□YES	□ио	□n/k	Liver dysfunction	□YES	□ио	□n/k
Endocarditis	□YES	□ио	□n/ĸ	Hyperglycaemia	□YES	□по	□n/k
Myocarditis/Pericarditis	□YES	□ио	□n/ĸ	Hypoglycaemia	□YES	□ио	□N/K
Cardiomyopathy	□YES	□ио	□n/k	Other, if yes specify below	□YES	□ио	□n/k
Cardiac arrhythmia	□YES	□ио	□n/k	Other:			

STUDY PARTICIPATION
Is / Has the participant being/ been recruited to a trial or multi-centre study during the period of their current illness (including
initiation in the community and hospital)? $\square$ YES $\square$ NO
If YES , specify
Name of study
Study Participant ID
Add another study? ☐ YES ☐ NO
If YES , specify
Name of study
Study Participant ID
Add another study? ☐ YES ☐ NO
If YES , specify
Name of study
Study Participant ID





Page 4 of 4

OUTCOME: (complete at discharge, transfer death	or DAY 28, whicheve	er occurs first)					
Outcome: Discharged alive expected to survive							
☐ Hospitalisation = Remains in Hospital ≥ Day 28 after symptom onset							
- if Hospitalisation   Ongoing health care needs relating to this admission							
OR							
Ongoing health care needs NOT related to this episode							
OR							
☐ Medically fit for discharge but remains in hospital for other reason (e.g. awaiting suitable care in community, resident in long term health care or mental health facility)							
☐ <u>Transfer to other facility</u> ☐ <u>Palliativ</u>	e discharge	□ <u>Death</u>	□ <u>N/K</u>				
Outcome date: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_2	_][_Y_] □ N/K						
If Discharged alive:							
Ability to self-care at discharge versus before illness: ☐ Same as before illness ☐ Worse ☐ Better ☐ N/K							
If Discharged alive: Post-discharge treatment: Oxygen therapy? ☐ YES ☐ NO ☐ N	′K						
If Transferred: Facility name: \ \_\ N/K							
If Transferred: Is the transfer facility a study site? $\square$ YES $\square$ NO $\square$ N/K							
If a Study Site: Participant ID # at new facility: ☐ Same as above							
☐ Different: [][][]- [][][] ☐N/K							
PREGNANCY OUTCOME: If delivered during admiss	ion, please confirm:						
POST PARTUM (within six weeks of delivery)? ☐YES ☐NO or	 □n/k						
Pregnancy Outcome: □Live birth □Still birth Delive	ry date: [_D_][_D_]/[_M	1_][_M_]/[_2_][_0_][_2_][_)	<b>/_</b> ]				
Has infant(s) been tested for Mother's infection? □YES □NO □N/K If YES: □Positive □Negative							
IF POSITIVE PLEASE COMPLETE A SEPARATE CASE REPORT FORM FOR THE INFANT(s)							



PARTICIPANT ID I I I I I	11	11	l I	11	11	11	11

### ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK WITHDRAWAL FORM Page 1 of 1

WITHDRAWAL
Date of withdrawal:D_](_D_]/[_M_](_M_]/[_2_](_0_](_2_](_Y_)
Type of withdrawal: ☐ Withdrawal from samples only ☐ Other Please specify:
Reason for withdrawal:



PARTICIPANT ID I	1.1	1.1	1.1	1.1	1 1	1.1	1.1	1.1	11
								1 1	

### ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections UK Convalescent Sample Page 1 of 1

ISARIC CCP-UK RESEARCH SAMPLES	
Was a convalescent sample obtained?	□YES □NO
If yes, please record the KIT number:	KIT NUMBER [_C_] [_C_] [_P_] [] [][][]
Date sample obtained:	[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_2_][_Y_]